Cargando…

Changes in DNA methylation are associated with the development of drug resistance in cervical cancer cells

BACKGROUND AND PROPOSE: Changes in DNA methylation are associated with changes in somatic cell fate without the alteration of coding sequences. In addition to its use as a traceable biomarker, reversible DNA methylation could also serve as a therapeutic target. In particular, if the development of d...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Chih-Cheng, Lee, Kuan-Der, Pai, Mei-Yu, Chu, Pei-Yi, Hsu, Chia-Chen, Chiu, Chia-Chen, Chen, Li-Tzong, Chang, Jang-Yang, Hsiao, Shu-Huei, Leu, Yu-Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604021/
https://www.ncbi.nlm.nih.gov/pubmed/26464562
http://dx.doi.org/10.1186/s12935-015-0248-3
_version_ 1782394995965165568
author Chen, Chih-Cheng
Lee, Kuan-Der
Pai, Mei-Yu
Chu, Pei-Yi
Hsu, Chia-Chen
Chiu, Chia-Chen
Chen, Li-Tzong
Chang, Jang-Yang
Hsiao, Shu-Huei
Leu, Yu-Wei
author_facet Chen, Chih-Cheng
Lee, Kuan-Der
Pai, Mei-Yu
Chu, Pei-Yi
Hsu, Chia-Chen
Chiu, Chia-Chen
Chen, Li-Tzong
Chang, Jang-Yang
Hsiao, Shu-Huei
Leu, Yu-Wei
author_sort Chen, Chih-Cheng
collection PubMed
description BACKGROUND AND PROPOSE: Changes in DNA methylation are associated with changes in somatic cell fate without the alteration of coding sequences. In addition to its use as a traceable biomarker, reversible DNA methylation could also serve as a therapeutic target. In particular, if the development of drug resistance is associated with changes in DNA methylation, then demethylation might reverse the resistance phenotype. The reversion of the drug-resistance might then be feasible if the association between abnormal DNA methylation and the development of drug-resistance could be identified. METHODS: Methylation differences between the drug-resistance cervical cancer cell, SiHa, and its derived oxaliplatin-resistant S3 cells were detected by methylation specific microarray. The drug-resistance cells were treated with demethylation agent to see if the resistance phenotype were reversed. Targeted methylation of one of the identified locus in normal cell is expected to recapitulate the development of resistance and a two-component reporter system is adopted to monitor the increase of DNA methylation in live cells. RESULTS: In this report, we identified methylation changes, both genome-wide and within individual loci, in the oxaliplatin-resistant cervical cancer cell S3 compared with its parental cell line SiHa. Treatment of S3 with a demethylation agent reversed increases in methylation and allowed the expression of methylation-silenced genes. Treatment with the demethylation agent also restored the sensitivity of S3 to cisplatin, taxol, and oxaliplatin to the same level as that of SiHa. Finally, we found that methylation of the target gene Casp8AP2 is sufficient to increase drug resistance in different cells. CONCLUSIONS: These results suggest that global methylation is associated with the development of drug resistance and could serve as a biomarker and therapeutic target for drug resistance in cervical cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12935-015-0248-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4604021
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46040212015-10-14 Changes in DNA methylation are associated with the development of drug resistance in cervical cancer cells Chen, Chih-Cheng Lee, Kuan-Der Pai, Mei-Yu Chu, Pei-Yi Hsu, Chia-Chen Chiu, Chia-Chen Chen, Li-Tzong Chang, Jang-Yang Hsiao, Shu-Huei Leu, Yu-Wei Cancer Cell Int Primary Research BACKGROUND AND PROPOSE: Changes in DNA methylation are associated with changes in somatic cell fate without the alteration of coding sequences. In addition to its use as a traceable biomarker, reversible DNA methylation could also serve as a therapeutic target. In particular, if the development of drug resistance is associated with changes in DNA methylation, then demethylation might reverse the resistance phenotype. The reversion of the drug-resistance might then be feasible if the association between abnormal DNA methylation and the development of drug-resistance could be identified. METHODS: Methylation differences between the drug-resistance cervical cancer cell, SiHa, and its derived oxaliplatin-resistant S3 cells were detected by methylation specific microarray. The drug-resistance cells were treated with demethylation agent to see if the resistance phenotype were reversed. Targeted methylation of one of the identified locus in normal cell is expected to recapitulate the development of resistance and a two-component reporter system is adopted to monitor the increase of DNA methylation in live cells. RESULTS: In this report, we identified methylation changes, both genome-wide and within individual loci, in the oxaliplatin-resistant cervical cancer cell S3 compared with its parental cell line SiHa. Treatment of S3 with a demethylation agent reversed increases in methylation and allowed the expression of methylation-silenced genes. Treatment with the demethylation agent also restored the sensitivity of S3 to cisplatin, taxol, and oxaliplatin to the same level as that of SiHa. Finally, we found that methylation of the target gene Casp8AP2 is sufficient to increase drug resistance in different cells. CONCLUSIONS: These results suggest that global methylation is associated with the development of drug resistance and could serve as a biomarker and therapeutic target for drug resistance in cervical cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12935-015-0248-3) contains supplementary material, which is available to authorized users. BioMed Central 2015-10-13 /pmc/articles/PMC4604021/ /pubmed/26464562 http://dx.doi.org/10.1186/s12935-015-0248-3 Text en © Chen et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Primary Research
Chen, Chih-Cheng
Lee, Kuan-Der
Pai, Mei-Yu
Chu, Pei-Yi
Hsu, Chia-Chen
Chiu, Chia-Chen
Chen, Li-Tzong
Chang, Jang-Yang
Hsiao, Shu-Huei
Leu, Yu-Wei
Changes in DNA methylation are associated with the development of drug resistance in cervical cancer cells
title Changes in DNA methylation are associated with the development of drug resistance in cervical cancer cells
title_full Changes in DNA methylation are associated with the development of drug resistance in cervical cancer cells
title_fullStr Changes in DNA methylation are associated with the development of drug resistance in cervical cancer cells
title_full_unstemmed Changes in DNA methylation are associated with the development of drug resistance in cervical cancer cells
title_short Changes in DNA methylation are associated with the development of drug resistance in cervical cancer cells
title_sort changes in dna methylation are associated with the development of drug resistance in cervical cancer cells
topic Primary Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604021/
https://www.ncbi.nlm.nih.gov/pubmed/26464562
http://dx.doi.org/10.1186/s12935-015-0248-3
work_keys_str_mv AT chenchihcheng changesindnamethylationareassociatedwiththedevelopmentofdrugresistanceincervicalcancercells
AT leekuander changesindnamethylationareassociatedwiththedevelopmentofdrugresistanceincervicalcancercells
AT paimeiyu changesindnamethylationareassociatedwiththedevelopmentofdrugresistanceincervicalcancercells
AT chupeiyi changesindnamethylationareassociatedwiththedevelopmentofdrugresistanceincervicalcancercells
AT hsuchiachen changesindnamethylationareassociatedwiththedevelopmentofdrugresistanceincervicalcancercells
AT chiuchiachen changesindnamethylationareassociatedwiththedevelopmentofdrugresistanceincervicalcancercells
AT chenlitzong changesindnamethylationareassociatedwiththedevelopmentofdrugresistanceincervicalcancercells
AT changjangyang changesindnamethylationareassociatedwiththedevelopmentofdrugresistanceincervicalcancercells
AT hsiaoshuhuei changesindnamethylationareassociatedwiththedevelopmentofdrugresistanceincervicalcancercells
AT leuyuwei changesindnamethylationareassociatedwiththedevelopmentofdrugresistanceincervicalcancercells